Condition: Leber Congenital Amaurosis · Inherited Retinal Diseases Caused by RPE65 Mutations · Sponsor: HuidaGene Therapeutics Co., Ltd.
The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.
This description comes directly from the study's public registry record.
Study Director · 732-318-9873 · HG00402@huidagene.com
Always discuss trial participation with your own doctor first.
| Research Site | Sacramento, California, United States | Recruiting |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05906953